<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02182700</url>
  </required_header>
  <id_info>
    <org_study_id>1012.32</org_study_id>
    <nct_id>NCT02182700</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety of Combivent® Aerosol and Spacer, in Adult Patients With Moderate to Severe Asthma Crisis</brief_title>
  <official_title>Open Study on the Efficacy and Safety of Combivent® Aerosol (120 mcg Salbutamol Sulfate Plus 20 mcg Ipratropium Bromide) + Spacer, 12 to 24 Puffs, in Adult Patients With Moderate to Severe Asthma Crisis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      Study to evaluate the bronchodilator efficacy and safety of a fixed combination of salbutamol&#xD;
      sulfate (120 mcg) + ipratropium bromide (20mcg) (Combivent® MDI) in aerosol plus spacer in&#xD;
      adult patients with moderate-to-severe asthma crisis who arrived at the emergency room.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>July 1998</start_date>
  <primary_completion_date type="Actual">December 1999</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients discharged with a peak flow expiratory flow rate (PEFR) &gt;= 70% predicted normal value at the end of the first and the second treatment</measure>
    <time_frame>60 and 120 min after starting treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients whose PEFR &gt;= 60% within the first or the second hour</measure>
    <time_frame>60 and 120 min after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation period at the Intensive Care Unit (ICU)</measure>
    <time_frame>up to 3rd hour after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalisation time at the general ward</measure>
    <time_frame>up to 3rd hour after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of relapses and/or new episodes</measure>
    <time_frame>7 days after finishing treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">47</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Combivent® aerosol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>salbutamol sulfate + ipratropium bromide</intervention_name>
    <description>120 mcg (salbutamol sulfate) + 20 mcg (ipratropium bromide), inhalation (metered aerosol plus spacer)</description>
    <arm_group_label>Combivent® aerosol</arm_group_label>
    <other_name>Combivent® aerosol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female patients with a diagnosis of asthma according to the American Thoracic&#xD;
             Society (ATS) presenting at the emergency room with an acute moderate and/or severe&#xD;
             asthma attack&#xD;
&#xD;
          -  Patients aged between18 to 40 years&#xD;
&#xD;
          -  Patients able to perform spirometry (PEFR and FEV1)&#xD;
&#xD;
          -  PEFR &lt; 60% and &gt; 25 % of predicted normal value or a FEV1 &lt;= 60% of predicted normal&#xD;
             value&#xD;
&#xD;
          -  Patients able to sign witnessed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with very severe or life threatening obstruction, manifested by:&#xD;
&#xD;
               -  Cyanosis of tongue and lips&#xD;
&#xD;
               -  Confusion, drowsiness, coma or exhaustion&#xD;
&#xD;
               -  Silent chest on auscultation or weak respiratory effort&#xD;
&#xD;
               -  PEFR &lt; 25% the predicted normal value&#xD;
&#xD;
               -  Bradycardia (of less 60 beats/min)&#xD;
&#xD;
          -  Patients with a smoking history of more than 10 pack/years&#xD;
&#xD;
          -  Patients with chronic obstructive pulmonary disease (COPD)&#xD;
&#xD;
          -  Patients on treatment for or suspected as having glaucoma&#xD;
&#xD;
          -  Patients with uncontrolled hypertension&#xD;
&#xD;
          -  Patients with known allergy or contra-indications to either salbutamol, ipratropium or&#xD;
             hydrocortisone or their excipients&#xD;
&#xD;
          -  Female patients known or suspected to be pregnant or nursing&#xD;
&#xD;
          -  Patients known or suspected on clinical grounds to have pneumonia, pneumothorax or&#xD;
             pneumomediastinum&#xD;
&#xD;
          -  Patients with a history of chest surgery&#xD;
&#xD;
          -  Patients with other respiratory conditions if diagnosed. These included pulmonary&#xD;
             fibrosis, bronchiectasis, cystic fibrosis, pulmonary tuberculosis, pulmonary&#xD;
             complications of AIDS, lung cancer&#xD;
&#xD;
          -  Patients requiring drugs for the treatment of the acute asthma attack other than the&#xD;
             study drug, hydrocortisone or oxygen&#xD;
&#xD;
          -  Patients who have previously recruited into this study&#xD;
&#xD;
          -  Patients who have been on other investigational drugs within three months prior to&#xD;
             study entry&#xD;
&#xD;
          -  Patients with acute myocardial infarction, pulmonary edema or other life threatening&#xD;
             disease, which in the judgment of the ER (Emergency room) physician precluded entry&#xD;
             into the study&#xD;
&#xD;
          -  Patients with obvious or previous diagnosed serious hepatic or renal impairment or&#xD;
             bladder neck obstruction&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com/content/dam/internet/opu/clinicaltrial/com_EN/results/1012/1012.32_U02-3140.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2014</verification_date>
  <study_first_submitted>July 3, 2014</study_first_submitted>
  <study_first_submitted_qc>July 3, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2014</study_first_posted>
  <last_update_submitted>July 3, 2014</last_update_submitted>
  <last_update_submitted_qc>July 3, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromides</mesh_term>
    <mesh_term>Albuterol</mesh_term>
    <mesh_term>Ipratropium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

